Pubblicazioni del 2024

Studi: GOIRC-sponsored | Intergruppo | FICOG |BIG | GOIRC-facilitated

Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis DL, Proietto M, Cogoni A, Pasello G, Camerini A, Sperandi F, Colantonio I, Metro G, Mazzoni F, Baldini E, Veccia A, Bennicelli E, Cecilia Bettini A, Tognetto M, Ardizzoni A.

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.

Lung Cancer. 2024 Dec 15;199:108059. doi: 10.1016/j.lungcan.2024.108059. Online ahead of print.PMID: 39700681

Pellegrino B, Giovanardi F, Tibaldi C, Moscetti L, Vingiani A, Calabrò L, Zoppoli G, Didone S, Ferrando L, Franceschi E, Todeschini R, Tognetto M, Leonetti A, Minari R, Tommasi C, Serra O, Boni L, Pruneri G, Musolino A.
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Tumori. 2024 Dec 15:3008916241302919. doi: 10.1177/03008916241302919. Online ahead of print.PMID: 39676332

Pinto C, Orlandi A, Normanno N, Maiello E, Calegari MA, Antonuzzo L, Bordonaro R, Zampino MG, Pini S, Bergamo F, Tonini G, Avallone A, Latiano TP, Rosati G, Cogoni AA, Ballestrero A, Zaniboni A, Roselli M, Tamberi S, Barone C.

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study.

J Clin Oncol. 2024 Jan 5:JCO2301021. doi: 10.1200/JCO.23.01021. Online ahead of print.PMID: 38181312

Caminiti C, Maglietta G, Arenare L, Di Liello R, Migliaccio G, Barberio D, De Laurentiis M, Di Rella F, Nuzzo F, Pacilio C, Iodice G, Orditura M, Ciardiello F, Di Bella S, Cavanna L, Porta C, Giovanardi F, Ripamonti CI, Bilancia D, Aprile G, Ruelle T, Diodati F, Piccirillo MC, Iannelli E, Pinto C, Perrone F.

Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study.

Breast. 2024 Oct;77:103781. doi: 10.1016/j.breast.2024.103781. Epub 2024 Jul 20.PMID: 39059033

Nader-Marta G, Singer C, Hlauschek D, DeMichele A, Tarantino P, de Azambuja E, Pfeiler G, Martin M, Balko JM, Nowecki Z, Balic M, Brufsky AM, Chan A, Morris PG, Haddad T, Loibl S, Liu Y, Soelkner L, Fesl C, Mayer EL, Gnant M; PALLAS groups and investigators.

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Breast Cancer Res. 2024 Oct 7;26(1):140. doi: 10.1186/s13058-024-01899-2.PMID: 39375745 

E de Azambuja, M Piccart-Gebhart, S Fielding, J Townend, D W Hillman, M Colleoni, R Roylance, C M Kelly, J Lombard, S El-Abed, A Choudhury, L Korde, M Vicente, S Chumsri, R Rodeheffer, S L Ellard, A C Wolff, J Holtschmidt, I Lang, M UntchF Boyle, B Xu, G Werutsky, J Tujakowski, C-S Huang, N B Baruch, J Bliss, A Ferro, J Gralow, S-B Kim, J R Kroep, I Krop, S Kuemmel, R McConnell, L Moscetti, A S Knop, F van Duijnhoven, H Gomez, D Cameron, S Di Cosimo, R D Gelber, A Moreno-Aspitia

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

ESMO Open. 2024 Oct 16;9(11):103938.  doi: 10.1016/j.esmoop.2024.103938. Online ahead of print

Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M; APHINITY Steering Committee and Investigators.

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

J Clin Oncol. 2024 Nov;42(31):3643-3651. doi: 10.1200/JCO.23.02505. Epub 2024 Sep 11.PMID: 39259927

Tommasi C, Airò G, Pratticò F, Testi I, Corianò M, Pellegrino B, Denaro N, Demurtas L, Dessì M, Murgia S, Mura G, Wekking D, Scartozzi M, Musolino A, Solinas C.J

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies.

Clin Med. 2024 Mar 24;13(7):1873. doi: 10.3390/jcm13071873.PMID: 38610638 - Review.

Canino F, Tornincasa A, Bettelli S, Manfredini S, Barbolini M, Moscetti L, Omarini C, Toss A, Tamburrano F, Antonelli G, Baglio F, Belluzzi L, Martinelli G, Natalizio S, Ponzoni O, Dominici M, Piacentini F.

Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients.

F.Int J Mol Sci. 2024 Feb 20;25(5):2490. doi: 10.3390/ijms25052490.PMID: 38473737

Petrelli A, Rizzolio S, Pietrantonio F, Bellomo SE, Benelli M, De Cecco L, Romagnoli D, Berrino E, Orrù C, Ribisi S, Moya-Rull D, Migliore C, Conticelli D, Maina IM, Puliga E, Serra V, Pellegrino B, Llop-Guevara A, Musolino A, Siena S, Sartore-Bianchi A, Prisciandaro M, Morano F, Antista M, Fumagalli U, De Manzoni G, Degiuli M, Baiocchi GL, Amisano MF, Ferrero A, Marchiò C, Corso S, Giordano S.

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.

Cancer Res. 2023 May 15;83(10):1699-1710. doi: 10.1158/0008-5472.CAN-22-2620.PMID: 37129948

Casartelli C, Tommasi C, Lazzarin A, Corianò M, Tornali C, Serra O, Campanini N, Gutiérrez-Enríquez S, Sikokis A, Zanoni D, Minari R, Bortesi B, Michiara M, Boggiani D, Uliana V, Llop-Guevara A, Serra V, Musolino A, Pellegrino B.

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents.

ESMO Open. 2024 Jul 5;9(7):103629. doi: 10.1016/j.esmoop.2024.103629. Online ahead of print.PMID: 38970842